{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "exchange": "PNK", "shortName": "GRIFOLS SA SPON ADR EA REPR 1/2", "longName": "Grifols, S.A.", "messageBoardId": "finmb_734865", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 20.315575, "regularMarketPrice": 6.1, "marketState": "PRE", "firstTradeDateMilliseconds": 1263997800000, "priceHint": 2, "regularMarketChange": 1.0299997, "regularMarketTime": 1684179425, "regularMarketDayHigh": 6.26, "regularMarketDayRange": "6.1 - 6.26", "regularMarketDayLow": 6.1, "regularMarketVolume": 4490, "regularMarketPreviousClose": 5.07, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Other OTC", "financialCurrency": "EUR", "regularMarketOpen": 6.26, "averageDailyVolume3Month": 3063, "averageDailyVolume10Day": 11430, "fiftyTwoWeekLowChange": 2.4099998, "fiftyTwoWeekLowChangePercent": 0.65311646, "fiftyTwoWeekRange": "3.69 - 11.0", "fiftyTwoWeekHighChange": -4.9, "fiftyTwoWeekHighChangePercent": -0.44545457, "fiftyTwoWeekLow": 3.69, "fiftyTwoWeekHigh": 11.0, "dividendDate": 1623628800, "trailingAnnualDividendRate": 0.0, "trailingPE": 35.88235, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 0.17, "sharesOutstanding": 1356819968, "bookValue": 4.518, "fiftyDayAverage": 5.0076, "fiftyDayAverageChange": 1.0924001, "fiftyDayAverageChangePercent": 0.21814844, "twoHundredDayAverage": 5.582, "twoHundredDayAverageChange": 0.5180001, "twoHundredDayAverageChangePercent": 0.09279831, "marketCap": 8506876928, "priceToBook": 1.3501549, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "symbol": "GIKLY"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Avinguda de la Generalitat, 152", "address2": "Parc de Negocis Can Sant Joan Sant Cugat del Valles", "city": "Barcelona", "zip": "08174", "country": "Spain", "phone": "34 93 571 05 00", "fax": "34 93 800 80 00", "website": "https://www.grifols.com", "industry": "Drug Manufacturers\u2014General", "industryDisp": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Grifols, S.A. a plasma therapeutic company, engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives in Spain, the United States, Canada and internationally. The company operates through Biopharma, Diagnostic, Bio Supplies, and Others segments. The Biopharma segment researches, develops, produces, and markets plasma derivative products and therapies to treat patients with chronic, acute, and life-threatening diseases. It provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag, Human Albumin Grifols/Plasbumin Albumin, Vistaseal/Veraseal, and Tavlesse Fostamatinib Disodium Hexahydrate Film Coated tablets. The Diagnostic segment researches, develops, manufactures, and markets in vitro diagnostics products, including analytical instruments, reagents, software and associated products for use in clinical and blood bank laboratories and hospital products. It provides transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare Solutions, which provides services and manufactures products used by hospitals, blood banks, plasma collection centers and other healthcare systems, as well as parenteral solutions, robotics, and software. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.", "fullTimeEmployees": 26326, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas H. Glanzmann", "age": 64, "title": "Exec. Chairman", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 164040, "fmt": "164.04k", "longFmt": "164,040"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Raimon  Grifols Roura", "age": 58, "title": "Co-CEO & Exec. Vice-Chairman", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 1137344, "fmt": "1.14M", "longFmt": "1,137,344"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. V\u00edctor  Grifols Deu", "age": 45, "title": "Co-CEO & Exec. Director", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": {"raw": 1137344, "fmt": "1.14M", "longFmt": "1,137,344"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alfredo Arroyo  Guerra", "age": 64, "title": "CFO & VP", "yearBorn": 1958, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mrs. Eva  Bastida Tubau", "title": "Corp. VP and Director of Scientific & Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Nuria Pascual Lape\u00f1a", "age": 58, "title": "VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David Ian Bell", "age": 68, "title": "Chief Corp. Devel., Legal & Data Protection Officer", "yearBorn": 1954, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mateo Florencio Borr\u00e1s  Humbert", "age": 66, "title": "Corp. VP & Chief HR Officer", "yearBorn": 1956, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Maria  Teresa-Rion\u00e9 Llano", "age": 57, "title": "Chief Communications Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Montserrat Gaja Llamas", "age": 57, "title": "Chief HR Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 4, "shareHolderRightsRisk": 6, "overallRisk": 4, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}